Open AccessPhase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Author(s) -
Barbara Pistilli,
Timothy Pluard,
Ander Urruticoechea,
Daniele Farci,
Anthony Kong,
Thomas Bachelot,
Sy Chan,
Hyo S. Han,
Guy Jérusalem,
Patrick Urban,
Douglas Robinson,
S Le Mouhaër,
Emmanuelle di Tomaso,
Cristian Massacesi,
Cristina Saura
Publication year - 2017
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-017-4596-7
Subject(s) - medicine , trastuzumab , tolerability , breast cancer , oncology , phases of clinical research , metastatic breast cancer , regimen , capecitabine , adverse effect , cancer , clinical endpoint , chemotherapy , clinical trial , colorectal cancer
A Phase Ib study in patients with trastuzumab-resistant, human epidermal growth factor receptor-2- (HER2)-positive advanced breast cancer defined the recommended Phase II dose of buparlisib as 100 mg/day in combination with 2 mg/kg weekly trastuzumab, and reported preliminary signs of clinical activity. Here we present results from the Phase II portion.